C61
Conditions
Interventions
Group 1: This retrospective study examines 68Ga-PSMA-PET/CTs of all patients, who underwent 177Lu-PSMA radiologand therapy between April 2019 and December 2025.
Sponsors
Universitätsklinikum Halle (Saale), Abteilung für Nuklearmedizin
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The sample size includes all patients with mCRPC, who have been treated with 177Lu-PSMA radioligand therapy between April 2019 and December 2025.
Exclusion criteria
Exclusion criteria: missing data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between baseline total leasion activity (TLA [SUV-bw x cm³]) and baseline mean standard uptake value (SUVmean [kBq/ml]) of the respective organ. Total lesian activity as a mesuare for total tumor burden. | — |
Secondary
| Measure | Time frame |
|---|---|
| • changes in mean standard uptake value of healthy organs before and after 4 cycles of 177Lutetium-PSMA radioligand therapy (?SUVmean of the respective organ). Mean standard uptake value as a measure for uptake of PSMA-ligands in healthy organs. • changes in correlation between baseline and post radioligand therapy total lesion activity (?TLA) und changes in correlations between baseline und post radioligand therapy mean standard uptake value (?SUVmean) | — |
Countries
Germany
Contacts
Public ContactAlexander Heinzel
Universitätsklinikum Halle (Saale), Abteilung für Nuklearmedizin
Outcome results
None listed